ABSTRACT
Objective To explore the risk factors that may cause recurrent retinal detachment in rhegmatogenous retinal detachment(RRD)patients after surgery.Methods A total of 403 patients(403 eyes)with RRD diagnosed in the Department of Ophthalmology of the First Affiliated Hospital of Soochow University from October 2020 to April 2022 were included in this study.Among them,35 patients underwent the scleral buckling,79 patients underwent the pars plana vit-rectomy(PPV)+intravitreal gas tamponade,222 patients underwent the PPV+intravitreal silicone oil tamponade,and 67 patients underwent the PPV+vitreous silicone oil tamponade+silicone oil removal.The postoperative follow-up lasted for at least 3 months.Risk factors affecting one-time retinal reattachment after RRD surgery were analyzed by univariate and multivariate Logistic analyses,and Logistic regression was applied to construct a risk prediction model.Results Among the 403 eyes with RRD,369 eyes had retinal reattachment on the first try,and 34 eyes did not,with a one-time reat-tachment rate of 91.6%.The univariate analysis showed that the differences in axial length(AL),surgical approach,loca-tion of the tear,and size of the tear between patients with one-time retinal reattachment and those without reattachment were statistically significant(all P<0.05).From the regression equation,it was found that the risk of non-reattachment af-ter RRD surgery of patients with an AL ≥ 26 mm was 4.248 times higher than those with an AL<26 mm(P<0.05).The multivariate Logistic regression analysis showed that AL,location of the tear,size of the tear,and surgical approach were risk factors for non-reattachment after RRD surgery(all P<0.05).The Hosmer-Lemeshow test yielded P=0.165.The re-sults of the receiver operating characteristic curve analysis showed that the area under the curve to predict whether retinal re-detachment occurs after RRD surgery was 0.892(95%CI:0.832-0.953),and the sensitivity and specificity were 79.4%and 87.3%,respectively(P<0.05).Conclusion AL is an independent risk factor for retinal re-detachment after RRD surgery.The prediction model constructed based on AL,location of the tear,size of the tear,and the surgical method can accurately predict whether retinal detachment will occur after RRD surgery.
ABSTRACT
Purpose@#This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practice. @*Materials and Methods@#This was a prospective, single-arm, phase 2 trial conducted at three institutions in China. Patients with HER2-positive MBC, who had previously been treated with trastuzumab plus a taxane or trastuzumab plus pertuzumab combined with a chemotherapeutic agent, were enrolled between March 2020 and December 2021. All patients received pyrotinib 400 mg orally once daily plus vinorelbine 25 mg/m2 intravenously or 60-80 mg/m2 orally on day 1 and day 8 of 21-day cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival, and safety. @*Results@#A total of 39 patients were enrolled. All patients had been pretreated with trastuzumab and 23.1% (n=9) of them had accepted trastuzumab plus pertuzumab. The median follow-up time was 16.3 months (95% confidence interval [CI], 5.3 to 27.2), and the median PFS was 6.4 months (95% CI, 4.0 to 8.8). The ORR was 43.6% (95% CI, 27.8% to 60.4%) and the DCR was 84.6% (95% CI, 69.5% to 94.1%). The median PFS of patients with versus without prior pertuzumab treatment was 4.6 and 8.3 months (p=0.017). The most common grade 3/4 adverse events were diarrhea (28.2%), neutrophil count decreased (15.4%), white blood cell count decreased (7.7%), vomiting (5.1%), and anemia (2.6%). @*Conclusion@#Pyrotinib plus vinorelbine showed promising efficacy and tolerable toxicity as second-line treatment in patients with HER2-positive MBC.
ABSTRACT
This paper aims to explore the main points of diagnosis, treatment and misdiagnosis of conversion disorder characterized by paroxysmal abdominal pain. The general hospitals had a high misdiagnose rate and no effective symptomatic treatment for conversion disorder patients with physical discomfort as main symptoms, which leading to heavy physical and mental burden of patients and waste of medical resources, so this paper retrospectively analyzed the etiology, diagnostic process, treatment and therapeutic effect of a case of conversion disorder with paroxysmal abdominal pain as the main symptom. Case analysis showed that the physical discomfort as chief complain of conversion disorder patients affected the rate of early correct diagnosis and treatment, so clinicians' ability of diagnosis and differential diagnosis of conversion disorder needs to be strengthened. At the same time, cognitive behavioral therapy (CBT) is effective in the clinical treatment and recurrence prevention of conversion disorder.